2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa
- PMID: 34235889
- DOI: 10.1002/acr.24633
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa
Abstract
Objective: To provide evidence-based recommendations and expert guidance for the management of systemic polyarteritis nodosa (PAN).
Methods: Twenty-one clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for systemic, non-hepatitis B-related PAN. Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel.
Results: We present 16 recommendations and 1 ungraded position statement for PAN. Most recommendations were graded as conditional due to the paucity of evidence. These recommendations support early treatment of severe PAN with cyclophosphamide and glucocorticoids, limiting toxicity through minimizing long-term exposure to both treatments, and the use of imaging and tissue biopsy for disease diagnosis. These recommendations endorse minimizing risk to the patient by using established therapy at disease onset and identify new areas where adjunctive therapy may be warranted.
Conclusion: These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and imaging for patients with PAN.
© 2021 American College of Rheumatology. This article has been contributed to by US Government employees and their work is in the public domain in the USA.
Similar articles
-
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa.Arthritis Rheumatol. 2021 Aug;73(8):1384-1393. doi: 10.1002/art.41776. Epub 2021 Jul 8. Arthritis Rheumatol. 2021. PMID: 34235883
-
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.Arthritis Care Res (Hoboken). 2021 Aug;73(8):1071-1087. doi: 10.1002/acr.24632. Epub 2021 Jul 8. Arthritis Care Res (Hoboken). 2021. PMID: 34235871
-
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Arthritis Care Res (Hoboken). 2021 Aug;73(8):1088-1105. doi: 10.1002/acr.24634. Epub 2021 Jul 8. Arthritis Care Res (Hoboken). 2021. PMID: 34235880
-
Clinical Approach to Diagnosis and Therapy of Polyarteritis Nodosa.Curr Rheumatol Rep. 2021 Feb 10;23(3):14. doi: 10.1007/s11926-021-00983-2. Curr Rheumatol Rep. 2021. PMID: 33569653 Review.
-
Treatment of systemic necrotizing vasculitides: recent advances and important clinical considerations.Expert Rev Clin Immunol. 2019 Sep;15(9):939-949. doi: 10.1080/1744666X.2019.1656527. Epub 2019 Aug 26. Expert Rev Clin Immunol. 2019. PMID: 31414912 Review.
Cited by
-
Vasculitis in Children.Turk Arch Pediatr. 2024 Nov 1;59(6):517-526. doi: 10.5152/TurkArchPediatr.2024.24181. Turk Arch Pediatr. 2024. PMID: 39540696 Free PMC article. Review.
-
Central Nervous System Involvement in Systemic Autoimmune Rheumatic Diseases-Diagnosis and Treatment.Pharmaceuticals (Basel). 2024 Aug 7;17(8):1044. doi: 10.3390/ph17081044. Pharmaceuticals (Basel). 2024. PMID: 39204149 Free PMC article. Review.
-
Deficiency of adenosine deaminase 2: a genetic autoinflammatory disorder mimicking childhood polyarteritis nodosa.BMJ Case Rep. 2024 May 9;17(5):e258410. doi: 10.1136/bcr-2023-258410. BMJ Case Rep. 2024. PMID: 38724212
-
A Successful Infliximab Treatment of a Pediatric Case of Severe Polyarteritis Nodosa With a Cerebral Infarction and a Decreased Adenosine Deaminase 2 Activity.Cureus. 2023 Oct 30;15(10):e47952. doi: 10.7759/cureus.47952. eCollection 2023 Oct. Cureus. 2023. PMID: 38034163 Free PMC article.
-
Comprehensive Management of Vasculitis and Suspected Polyarteritis Nodosa in an Older Patient.Cureus. 2023 Mar 17;15(3):e36307. doi: 10.7759/cureus.36307. eCollection 2023 Mar. Cureus. 2023. PMID: 37077614 Free PMC article.
References
-
- Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 2013;65:1-11.
-
- Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group database. Arthritis Rheum 2010;62:616-26.
-
- Hernandez-Rodriguez J, Alba MA, Prieto-Gonzalez S, Cid MC. Diagnosis and classification of polyarteritis nodosa [review]. J Autoimmun 2014;48-49:84-9.
-
- Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
-
- Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 2013;66:719-25.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
